Early in 2023, new guidelines were published by the American Society of Anesthesiologists (ASA) to provide best practices in the monitoring and reversal of neuromuscular blockade. A key component of these updated guidelines was the appropriate use of an antagonist agent, including appropriate choice and dosage of a therapeutic agent. While the selection of a reversal agent is highly dependent on an accurate assessment of the depth of neuromuscular blockade, the relationship between the depth of blockade and pharmacologic antagonism is not well understood by many clinicians, resulting in inappropriate therapy selection and inappropriate dosing.
In the final episode of this CMEOCast podcast series, expert faculty will discuss the use of deep neuromuscular blockade to facilitate optimal surgical conditions and provide learners with strategies to effectively utilize best practices in the pharmacologic reversal of neuromuscular blockade ideally guided by quantitative monitoring techniques.
Utilize best practices in the pharmacologic reversal of neuromuscular blockade.
Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Physicians, nurse practitioners (NPs), physician associates (PAs), nurses, and pharmacists specializing in anesthesiology or surgery
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Renew reports the following financial relationships:
Research Support: Merck & Co., Inc (Funds to Mayo Clinic)
Dr. Makey reports no financial relationships to disclose.
Dr. Riddle reports the following financial relationships:
Speakers Bureau: Acacia Pharma/Eagle Pharmaceuticals, Inc.
Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).